Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced initial clinical data from VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of tremtelectogene empogeditemcel or “trem-cel” (formerly VOR33) in patients with acute myeloid leukemia (AML). The data observed from the first treated patient support the potential of a trem-cel transplant to be successfully manufactured, to engraft normally, and to maintain blood counts following treatment with the CD33-targeted therapy Mylotarg. The clinical trial continues to enroll patients and additional data are expected in 2023.
Conference Call & Webcast Information
Members of the Vor Bio management team, joined by Dr. Brenda Cooper, will conduct a live conference call and webcast today at 8:00 am Eastern Time.
Listeners can register for the webcast via this link.
Analysts wishing to participate in the Q&A session should use this link.
A replay of the webcast will be available via the investor section of the Company’s website at www.vorbio.com approximately two hours after the call’s conclusion.
https://finance.yahoo.com/news/first-aml-patient-successfully-transplanted-123000776.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.